Exercise Training in Heart Failure Patients With Persistent Atrial Fibrillation: a Practical Approach

A hallmark symptom of chronic heart failure (CHF) is exercise intolerance associated with early fatigue and/or dyspnoea with a minimal degree of exertion. It is also associated with a decline in capacity to perform activities of daily living and a diminished quality of life (QoL). Both patients with heart failure with reduced left ventricular ejection fraction (HFrEF) and those with heart failure with preserved ejection fraction (HFpEF) have poorer prognostic risk factors, including increased mortality.1

Predictors of Post-discharge Mortality Among Patients Hospitalized for Acute Heart Failure

Hospitalisation is a critical event in the clinical course of heart failure (HF) and despite relatively rapid relief of symptoms, hospitalisation is followed by an increased risk of death and re-hospitalisation.1 While performance measures have been developed in the last few years with the intent of improving post-discharge outcomes, post-discharge mortality rates remain unchanged or have slightly worsened.2 The mechanisms of these high post-discharge event rates are incompletely understood3 and, to date, no treatment has improved such o

The Impact of an Atrial Septal Defect on Hemodynamics in Patients With Heart Failure

Pulmonary venous hypertension and congestion that occurs with left ventricular (LV) failure is generally not seen in the presence of a large atrial septal defect (ASD). As long as right ventricular (RV) function and distensibility are not impaired, the ASD provides an alternate pathway for atrial emptying, thus preventing or attenuating elevated LV filling pressures.

Cardiac Atrophy and Heart Failure In Cancer

Cancer and the anti-cancer treatments prescribed by oncologists have long been known to have significant effects on muscle, causing a catabolic muscle wasting state and resulting in widespread and progressive atrophy of most muscle groups.1 This process contributes significantly to the cancer cachexia seen in up to 80 % of all patients with cancer, resulting in progressive weight loss, loss of muscle mass and decline in functional abilities.2 Cardiac atrophy describes the reduction in myocardial mass caused by a combination of a reduction in cell size

Cancer and Heart Failure: Understanding the Intersection

Heart disease and cancer are the two leading causes of death, together accounting for almost 50 % of deaths in the US.1 Unfortunately, the tremendous success in improving cancer survival is often attenuated by downstream cardiovascular complications from cancer therapy. Acute cardiac toxicity may limit the ability to use life-saving cancer therapy and chronic toxicity limits overall survival. As novel agents with more specific targets become available, unanticipated cardiac complications arise.